CROs poised to grow despite shift in biotech funding
After reaching historically-high multiples in 2021, a shift in biotech funding is raising doubts about the industry’s growth prospects. Investors are overlooking positive signs, argues Ann Hynes, Senior US Healthcare Equity Research Analyst.